CRNX
Price
$31.12
Change
+$0.50 (+1.63%)
Updated
Apr 2, 02:52 PM (EDT)
Capitalization
2.85B
36 days until earnings call
LGND
Price
$108.73
Change
+$3.91 (+3.73%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
2.02B
28 days until earnings call
Ad is loading...

CRNX vs LGND

Header iconCRNX vs LGND Comparison
Open Charts CRNX vs LGNDBanner chart's image
Crinetics Pharmaceuticals
Price$31.12
Change+$0.50 (+1.63%)
Volume$816
Capitalization2.85B
Ligand Pharmaceuticals
Price$108.73
Change+$3.91 (+3.73%)
Volume$15.6K
Capitalization2.02B
CRNX vs LGND Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. LGND commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and LGND is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (CRNX: $30.62 vs. LGND: $104.82)
Brand notoriety: CRNX and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 224% vs. LGND: 87%
Market capitalization -- CRNX: $2.85B vs. LGND: $2.02B
CRNX [@Biotechnology] is valued at $2.85B. LGND’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while LGND’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 4 bearish.
  • LGND’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than LGND.

Price Growth

CRNX (@Biotechnology) experienced а -12.69% price change this week, while LGND (@Biotechnology) price change was -4.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.95%. For the same industry, the average monthly price growth was -7.12%, and the average quarterly price growth was -11.69%.

Reported Earning Dates

CRNX is expected to report earnings on May 08, 2025.

LGND is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-4.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.85B) has a higher market cap than LGND($2.02B). LGND YTD gains are higher at: -2.175 vs. CRNX (-40.113). LGND has higher annual earnings (EBITDA): 40.8M vs. CRNX (-336.07M). CRNX has more cash in the bank: 1.35B vs. LGND (256M). LGND has less debt than CRNX: LGND (7.11M) vs CRNX (51.7M). LGND has higher revenues than CRNX: LGND (167M) vs CRNX (1.04M).
CRNXLGNDCRNX / LGND
Capitalization2.85B2.02B141%
EBITDA-336.07M40.8M-824%
Gain YTD-40.113-2.1751,845%
P/E RatioN/A46.19-
Revenue1.04M167M1%
Total Cash1.35B256M529%
Total Debt51.7M7.11M728%
FUNDAMENTALS RATINGS
CRNX vs LGND: Fundamental Ratings
CRNX
LGND
OUTLOOK RATING
1..100
5675
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
6561
SMR RATING
1..100
9591
PRICE GROWTH RATING
1..100
8554
P/E GROWTH RATING
1..100
10089
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LGND's Valuation (78) in the Biotechnology industry is in the same range as CRNX (90) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to CRNX’s over the last 12 months.

LGND's Profit vs Risk Rating (61) in the Biotechnology industry is in the same range as CRNX (65) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to CRNX’s over the last 12 months.

LGND's SMR Rating (91) in the Biotechnology industry is in the same range as CRNX (95) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to CRNX’s over the last 12 months.

LGND's Price Growth Rating (54) in the Biotechnology industry is in the same range as CRNX (85) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to CRNX’s over the last 12 months.

LGND's P/E Growth Rating (89) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXLGND
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 14 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGEIX16.62N/A
N/A
American Century Global Gold Inv
ALPCX10.57N/A
N/A
American Century Focused Lg Cap Val C
OIERX24.52N/A
N/A
JPMorgan Equity Income R5
ISPVX18.64N/A
N/A
Macquarie Smid Cap Core Fund R6
LFGQX30.88N/A
N/A
Lord Abbett Focused Growth R3

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with ELVN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-8.71%
ELVN - CRNX
51%
Loosely correlated
-4.07%
TRDA - CRNX
50%
Loosely correlated
-3.10%
INZY - CRNX
48%
Loosely correlated
-4.40%
IDYA - CRNX
48%
Loosely correlated
-9.83%
IGMS - CRNX
47%
Loosely correlated
N/A
More